GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Medlab Clinical Ltd (ASX:MDC) » Definitions » Profitability Rank

Medlab Clinical (ASX:MDC) Profitability Rank : 3 (As of Dec. 2023)


View and export this data going back to 2015. Start your Free Trial

What is Medlab Clinical Profitability Rank?

Medlab Clinical has the Profitability Rank of 3. It has had trouble to make a profit.

GuruFocus Profitability Rank ranks how profitable a company is and how likely the company's business will stay that way. It is based on these factors:

1. Operating Margin %
2. Piotroski F-Score
3. Trend of the Operating Margin % (5-year average). The company with an uptrend profit margin has a higher rank.
4. Consistency of the profitability
5. Predictability Rank

Medlab Clinical's Operating Margin % for the quarter that ended in Dec. 2023 was -4,162.50%. As of today, Medlab Clinical's Piotroski F-Score is 4.


Competitive Comparison of Medlab Clinical's Profitability Rank

For the Biotechnology subindustry, Medlab Clinical's Profitability Rank, along with its competitors' market caps and Profitability Rank data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Medlab Clinical's Profitability Rank Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Medlab Clinical's Profitability Rank distribution charts can be found below:

* The bar in red indicates where Medlab Clinical's Profitability Rank falls into.



Medlab Clinical Profitability Rank Calculation

GuruFocus Profitability Rank ranks how profitable a company is and how likely the company's business will stay that way.

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Medlab Clinical has the Profitability Rank of 3. It has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength. But if a company is consistently profitable, its financial strength will be stronger.

Profitability Rank is based on these factors:

1. Operating Margin %

Operating Margin % - also known as operating income margin, operating profit margin and return on sales (ROS) - is the ratio of Operating Income divided by net sales or Revenue, usually presented in percent.

Medlab Clinical's Operating Margin % for the quarter that ended in Dec. 2023 is calculated as:

Operating Margin %=Operating Income (Q: Dec. 2023 ) / Revenue (Q: Dec. 2023 )
=-1.998 / 0.048
=-4,162.50 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

2. Piotroski F-Score

The zones of discrimination were as such:

Good or high score = 8 or 9
Bad or low score = 0 or 1

Medlab Clinical has an F-score of 4 indicating the company's financial situation is typical for a stable company.

3. Trend of the Operating Margin % (5-year average). The company with an uptrend profit margin has a higher rank.

Warning Sign:

Medlab Clinical Ltd operating margin has been in a 5-year decline. The average rate of decline per year is -51.5%.

4. Consistency of the profitability

5. Predictability Rank


Medlab Clinical Profitability Rank Related Terms

Thank you for viewing the detailed overview of Medlab Clinical's Profitability Rank provided by GuruFocus.com. Please click on the following links to see related term pages.


Medlab Clinical (ASX:MDC) Business Description

Traded in Other Exchanges
N/A
Address
11 Lord Street, Unit 5, Botany, NSW, AUS, 2019
Medlab Clinical Ltd is a medical research and development company. It is engaged in researching and formulating novel biotherapeutics to improve health outcomes in early to moderate stage chronic diseases such as chronic kidney disease, pre-diabetes, and obesity. Some of the company's nutraceutical products are Multibiotic, Mg Optima Relax, NRGBiotic, NanoCelle D3, SB 5B and others. The principal segments of the group are Nutraceutical which includes the sale of nutraceutical products; and Pharmaceutical research. It generates the majority of the revenue from the sale of nutraceutical products. The business operations of the firm are carried out from Australia.